Please wait while the formulary information is being retrieved.
DAPSONE (DAPSONE)
- Leprosy
- Dermatitis herpetiformis
100 mg tablet
- 1 tablet (100 mg) by oral route once daily
25 mg tablet
- 1 tablet (25 mg) by oral route once daily
Actinomycotic mycetoma
- 1 tablet (100 mg) by oral route 2 times per day
Dermatitis herpetiformis
- 1 tablet (25 mg) by oral route once daily
- 2 tablets (50 mg) by oral route once daily
- 1 tablet (100 mg) by oral route once daily
- 2 tablets (200 mg) by oral route once daily
- 2 tablets (200 mg) by oral route 2 times per day
- 3 tablets (300 mg) by oral route once daily
Granuloma annulare
- 1 tablet (100 mg) by oral route once daily
Leprosy
- 2 tablets (50 mg) by oral route once daily
- 1 tablet (100 mg) by oral route once daily
Pneumocystis jiroveci pneumonia prevention
- 2 tablets (50 mg) by oral route once daily
- 1 tablet (100 mg) by oral route once daily
Pneumocystis jirovecii pneumonia
- 1 tablet (100 mg) by oral route once daily
Pyoderma gangrenosum
- 2 tablets (50 mg) by oral route once daily
- 1 tablet (100 mg) by oral route once daily
Subcorneal pustular dermatosis
- 1 tablet (100 mg) by oral route once daily
- None
Contraindicated
- didanosine
- Videx 2 Gram Pediatric
- Videx 4 Gram Pediatric
- Videx Ec
Severe
Moderate
- None
- Glucose-6-phosphate dehydrogenase (g6Pd) deficiency
- Hemolytic anemia from PK and g6PD deficiencies
- Severe anemia
Contraindicated
- NADH methemoglobin reductase deficiency
Severe
Moderate
- Disease of liver
DAPSONE (DAPSONE)
- Leprosy
- Dermatitis herpetiformis
- Allergic dermatitis
- Hemolytic anemia
- Methemoglobinemia
- Skin rash
- Urticaria
- None
More Frequent
Severe
Less Severe
- None
- None
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Agranulocytosis
- Altered mental status
- Anemia
- Blood dyscrasias
- Exfoliative dermatitis
- Fever
- Glucose-6-phosphate dehydrogenase deficiency anemia
- Hepatocellular damage
- Jaundice
- Lymphadenopathy
- Malaise
- Mood changes
- Peripheral neuropathy
- Pruritus of skin
Less Severe
- Anorexia
- Gastrointestinal irritation
- Headache disorder
- Insomnia
- Nausea
- Nervousness
- Vomiting
Contraindicated
Dapsone (oral)
Not recommended age < 1 month. Risk of hyperbilirubinemia.
- 1 Day – 29 Days
- 1 Not recommended age < 1 month. Risk of hyperbilirubinemia.
Severe Precaution
None
Management or Monitoring Precaution
None
Dapsone
- Severity Level:
2
- Additional Notes:
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Dapsone
Reports of hemolytic anemia; caution in g6Pd deficient persons
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Drug shown to have adverse effect | Reports of hemolytic anemia; caution in g6Pd deficient persons |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Dermatitis herpetiformis | |
| L12.2 | Chronic bullous disease of childhood |
| L13.0 | Dermatitis herpetiformis |
| Leprosy | |
| A30 | Leprosy [hansen's disease] |
| A30.0 | Indeterminate leprosy |
| A30.1 | Tuberculoid leprosy |
| A30.2 | Borderline tuberculoid leprosy |
| A30.3 | Borderline leprosy |
| A30.4 | Borderline lepromatous leprosy |
| A30.5 | Lepromatous leprosy |
| A30.8 | Other forms of leprosy |
| A30.9 | Leprosy, unspecified |
| 0-9 | A-Z |
|---|---|
| A30 | Leprosy [hansen's disease] |
| A30.0 | Indeterminate leprosy |
| A30.1 | Tuberculoid leprosy |
| A30.2 | Borderline tuberculoid leprosy |
| A30.3 | Borderline leprosy |
| A30.4 | Borderline lepromatous leprosy |
| A30.5 | Lepromatous leprosy |
| A30.8 | Other forms of leprosy |
| A30.9 | Leprosy, unspecified |
| L12.2 | Chronic bullous disease of childhood |
| L13.0 | Dermatitis herpetiformis |
Formulary Reference Tool